NIH grants funds to Boston Immune’s Phase I trial of TNFR2 antagonist
The company entered a research and exclusivity agreement with the McQuade Center for Strategic Research and Development.
19 August 2024
19 August 2024
The company entered a research and exclusivity agreement with the McQuade Center for Strategic Research and Development.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
GlobalData's latest report provides a granular forecast growth analysis for both global and regional chronic kidney disease markets through 2033. Per our estimates, the sales of CKD therapeutics across the 7MM will grow at a CAGR of >19% between 2023 and 2033. The launch of eight oral pipeline agents and six injectable pipeline agents will be the main drivers of the CKD market across the 7MM.
GlobalData's latest report provides a granular forecast growth analysis for both global and regional chronic kidney disease markets through 2033. Per our estimates, the sales of CKD therapeutics across the 7MM will grow at a CAGR of >19% between 2023 and 2033. The launch of eight oral pipeline agents and six injectable pipeline agents will be the main drivers of the CKD market across the 7MM.
GlobalData's latest report provides a granular forecast growth analysis for both global and regional chronic kidney disease markets through 2033. Per our estimates, the sales of CKD therapeutics across the 7MM will grow at a CAGR of >19% between 2023 and 2033. The launch of eight oral pipeline agents and six injectable pipeline agents will be the main drivers of the CKD market across the 7MM.
Give your business an edge with our leading industry insights.